Chiyue cheung - Aug 3, 2022 Form 4 Insider Report for NEOPHOTONICS CORP (NPTN)

Role
COO
Signature
/s/ John Sellers, Attorney-in-fact
Stock symbol
NPTN
Transactions as of
Aug 3, 2022
Transactions value $
$0
Form type
4
Date filed
8/5/2022, 05:14 PM
Previous filing
Aug 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NPTN Restricted Stock Unit (right to acquire) Disposed to Issuer -85.9K -100% 0 Aug 3, 2022 Common Stock 85.9K $0.00 Direct F1
transaction NPTN Performance Restricted Stock Unit (right to acquire) Disposed to Issuer -34.6K -100% 0 Aug 3, 2022 Common Stock 34.6K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Chiyue cheung is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated November 3, 2021, by and among the Issuer, Lumentum Holdings Inc., a Delaware corporation ("Lumentum"), and Neptune Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Lumentum ("Merger Sub"), on August 3, 2022 (the "Closing Date"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Lumentum. In connection with the Merger, Restricted Stock Unit Awards of the Issuer, outstanding and vested as of immediately prior to the Closing Date, were cancelled and converted into the right to receive $16.00 in cash, without interest, per share, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").
F2 Performance Stock Unit Awards of the Issuer, outstanding and vested as of immediately prior to the Closing Date, were cancelled and converted into the right to receive the Merger Consideration.

Remarks:

Exhibit List Exhibit 24: Authorization Letter